Cogent Biosciences, Inc.
COGT
Ранг среди акций
#3248
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Цена акции
$31.37
Рыночная капитализация
$5.44B
Изменение (1 день)
4.54%
Изменение (1 год)
93.42%
Страна
US
Торговля Cogent Biosciences, Inc. (COGT)
Категория
Healthcare
Коэффициент P/S для Cogent Biosciences, Inc. (COGT)
Коэффициент P/S на October 2026 TTM: 0.00
Согласно последним финансовым отчетам и цене акций Cogent Biosciences, Inc., текущий коэффициент P/S (TTM) составляет 0.00. В конце 2023 он составлял 0.00.
История P/S для Cogent Biosciences, Inc. с 2015 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | -100.00% |
| 2020 | 15.81 | 1,520.90% |
| 2019 | 0.98 | -91.33% |
| 2018 | 11.25 | -71.38% |
| 2017 | 39.32 | -3.98% |
| 2016 | 40.95 | -53.01% |
| 2015 | 87.14 | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
